The present invention relates to: an activity modulator which is a means for modulating the activity of CD300b-dependent phagocytosis; and medicine for the treatment or prevention of a disease or condition in which the activity is involved. The activity modulator comprises a CD300a-binding substance and modulates CD300b-dependent phagocytosis signals in a macrophage.